;PMID: 2021946
;source_file_1243.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..125] = [t:42..125]
;2)section:[e:129..194] = [t:129..194]
;3)section:[e:198..285] = [t:198..285]
;4)sentence:[e:289..608] = [t:289..608]
;5)sentence:[e:609..781] = [t:609..781]
;6)sentence:[e:782..831] = [t:782..831]
;7)sentence:[e:832..912] = [t:832..912]
;8)sentence:[e:913..1062] = [t:913..1062]
;9)sentence:[e:1063..1286] = [t:1063..1286]
;10)sentence:[e:1288..1358] = [t:1288..1358]
;11)section:[e:1362..1406] = [t:1362..1406]

;section 0 Span:0..37
;Cancer Res  1991 May 15;51(10):2690-3
(SEC
  (FRAG (NN:[0..6] Cancer) (NNP:[7..10] Res) (CD:[12..16] 1991)
        (MD:[17..20] May) (DT:[21..27] 15;51-LRB-) (CD:[27..29] 10)
        (-RRB-:[29..30] -RRB-) (CD:[30..35] :2690) (::[35..36] -)
        (CD:[36..37] 3)))

;sentence 1 Span:42..125
;High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient 
;area.
;[56..59]:gene-rna:"ras"
;[60..68]:variation-location:"codon 61"
;[69..77]:variation-event:"mutation"
;[81..95]:malignancy:"thyroid tumors"
(SENT
  (NP-HLN
    (NP (JJ:[42..46] High) (NNS:[47..52] rates))
    (PP (IN:[53..55] of)
      (NP (NN:[56..59] ras)
        (NML (NN:[60..65] codon) (CD:[66..68] 61))
        (NN:[69..77] mutation)))
    (PP-LOC (IN:[78..80] in)
      (NP (JJ:[81..88] thyroid) (NNS:[89..95] tumors)))
    (PP-LOC (IN:[96..98] in)
      (NP (DT:[99..101] an)
        (ADJP (NN:[102..108] iodide) (HYPH:[108..109] -)
              (JJ:[109..118] deficient))
        (NN:[120..124] area)))
    (.:[124..125] .)))

;section 2 Span:129..194
;Shi YF, Zou MJ, Schmidt H, Juhasz F, Stensky V, Robb D, Farid NR.
(SEC
  (FRAG (NNP:[129..132] Shi) (NNP:[133..135] YF) (,:[135..136] ,)
        (NNP:[137..140] Zou) (NNP:[141..143] MJ) (,:[143..144] ,)
        (NNP:[145..152] Schmidt) (NNP:[153..154] H) (,:[154..155] ,)
        (NNP:[156..162] Juhasz) (NNP:[163..164] F) (,:[164..165] ,)
        (NNP:[166..173] Stensky) (NNP:[174..175] V) (,:[175..176] ,)
        (NNP:[177..181] Robb) (NNP:[182..183] D) (,:[183..184] ,)
        (NNP:[185..190] Farid) (NNP:[191..193] NR) (.:[193..194] .)))

;section 3 Span:198..285
;Thyroid Research Laboratory, Health Sciences Centre, St. John's,
;Newfoundland,  Canada.
(SEC
  (FRAG (NNP:[198..205] Thyroid) (NNP:[206..214] Research)
        (NNP:[215..225] Laboratory) (,:[225..226] ,) (NNP:[227..233] Health)
        (NNPS:[234..242] Sciences) (NNP:[243..249] Centre) (,:[249..250] ,)
        (NNP:[251..254] St.) (NNP:[255..259] John) (POS:[259..261] 's)
        (,:[261..262] ,) (NNP:[263..275] Newfoundland) (,:[275..276] ,)
        (NNP:[278..284] Canada) (.:[284..285] .)))

;sentence 4 Span:289..608
;Using polymerase chain reaction and sequence-specific oligonucleotide 
;hybridization, the frequency of three ras oncogene mutations (N-ras, Ha-ras,
;and  K-ras) in thyroid tumors (25 adenomas, 16 follicular carcinomas, and 22 
;papillary carcinomas) was investigated in both iodide-deficient and 
;iodide-sufficient areas.
;[295..305]:gene-protein:"polymerase"
;[398..401]:gene-rna:"ras"
;[422..427]:gene-rna:"N-ras"
;[429..435]:gene-rna:"Ha-ras"
;[442..447]:gene-rna:"K-ras"
;[452..466]:malignancy:"thyroid tumors"
;[471..479]:malignancy:"adenomas"
;[484..505]:malignancy:"follicular carcinomas"
;[515..535]:malignancy:"papillary carcinomas"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[289..289] *))
      (VP (VBG:[289..294] Using)
        (NP
          (NP (NN:[295..305] polymerase) (NN:[306..311] chain)
              (NN:[312..320] reaction))
          (CC:[321..324] and)
          (NP
            (ADJP (NN:[325..333] sequence) (HYPH:[333..334] -)
                  (JJ:[334..342] specific))
            (NN:[343..358] oligonucleotide) (NN:[360..373] hybridization)))))
    (,:[373..374] ,)
    (NP-SBJ-2
      (NP (DT:[375..378] the) (NN:[379..388] frequency))
      (PP (IN:[389..391] of)
        (NP
          (NP (CD:[392..397] three)
            (NML (NN:[398..401] ras) (NN:[402..410] oncogene))
            (NNS:[411..420] mutations)
            (PRN (-LRB-:[421..422] -LRB-)
              (NP (NN:[422..427] N-ras) (,:[427..428] ,) (NN:[429..435] Ha-ras)
                  (,:[435..436] ,) (CC:[437..440] and) (NN:[442..447] K-ras))
              (-RRB-:[447..448] -RRB-)))
          (PP (IN:[449..451] in)
            (NP
               (JJ:[452..459] thyroid) (NNS:[460..466] tumors)
              (PRN (-LRB-:[467..468] -LRB-)
                (NP
                  (NP (CD:[468..470] 25) (NNS:[471..479] adenomas))
                  (,:[479..480] ,)
                  (NP (CD:[481..483] 16)
                     (JJ:[484..494] follicular) (NNS:[495..505] carcinomas))
                  (,:[505..506] ,) (CC:[507..510] and)
                  (NP (CD:[511..513] 22)
                     (JJ:[515..524] papillary) (NNS:[525..535] carcinomas)))
                (-RRB-:[535..536] -RRB-)))))))
    (VP (VBD:[537..540] was)
      (VP (VBN:[541..553] investigated)
        (NP-2 (-NONE-:[553..553] *))
        (PP-LOC (IN:[554..556] in)
          (NP (CC:[557..561] both)
            (NP
              (NML (NN:[562..568] iodide) (HYPH:[568..569] -)
                   (JJ:[569..578] deficient))
              (NML-1 (-NONE-:[578..578] *P*)))
            (CC:[579..582] and)
            (NP
              (NML (NN:[584..590] iodide) (HYPH:[590..591] -)
                   (JJ:[591..601] sufficient))
              (NML-1 (NNS:[602..607] areas)))))))
    (.:[607..608] .)))

;sentence 5 Span:609..781
;The ras oncogene mutation rate was significantly higher  in the
;iodide-deficient area, being 85 versus 17% in the adenomas, and 50 versus 
;10% in the follicular carcinomas.
;[613..616]:gene-rna:"ras"
;[723..731]:malignancy:"adenomas"
;[759..780]:malignancy:"follicular carcinomas"
(SENT
  (S
    (NP-SBJ (DT:[609..612] The)
      (NML (NN:[613..616] ras) (NN:[617..625] oncogene))
      (NN:[626..634] mutation) (NN:[635..639] rate))
    (VP (VBD:[640..643] was)
      (ADJP-PRD (RB:[644..657] significantly) (JJR:[658..664] higher))
      (PP (IN:[666..668] in)
        (NP (DT:[669..672] the)
          (ADJP (NN:[673..679] iodide) (HYPH:[679..680] -)
                (JJ:[680..689] deficient))
          (NN:[690..694] area)))
      (,:[694..695] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[695..695] *))
        (VP
          (VP (VBG:[696..701] being)
            (NP-PRD
              (NP (CD:[702..704] 85)
                (NML-2 (-NONE-:[704..704] *P*)))
              (PP (IN:[705..711] versus)
                (NP (CD:[712..714] 17)
                  (NML-2 (NN:[714..715] %)))))
            (PP (IN:[716..718] in)
              (NP (DT:[719..722] the) (NNS:[723..731] adenomas))))
          (,:[731..732] ,) (CC:[733..736] and)
          (VP
            (NP-PRD
              (NP (CD:[737..739] 50)
                (NML-1 (-NONE-:[739..739] *P*)))
              (PP (IN:[740..746] versus)
                (NP (CD:[748..750] 10)
                  (NML-1 (NN:[750..751] %)))))
            (PP-LOC (IN:[752..754] in)
              (NP (DT:[755..758] the)
                 (JJ:[759..769] follicular) (NNS:[770..780] carcinomas)))))))
    (.:[780..781] .)))

;sentence 6 Span:782..831
;No mutations were found in papillary  carcinomas.
;[809..830]:malignancy:"papillary  carcinomas"
(SENT
  (S
    (NP-SBJ-1 (DT:[782..784] No) (NNS:[785..794] mutations))
    (VP (VBD:[795..799] were)
      (VP (VBN:[800..805] found)
        (NP-1 (-NONE-:[805..805] *))
        (PP-LOC (IN:[806..808] in)
          (NP (JJ:[809..818] papillary) (NNS:[820..830] carcinomas)))))
    (.:[830..831] .)))

;sentence 7 Span:832..912
;The most common mutation site was Ha-ras codon 61 with Gln----Arg 
;substitution.
;[848..856]:variation-event:"mutation"
;[866..872]:gene-rna:"Ha-ras"
;[873..881]:variation-location:"codon 61"
;[887..890]:variation-state-original:"Gln"
;[894..897]:variation-state-altered:"Arg"
;[899..911]:variation-type:"substitution"
(SENT
  (S
    (NP-SBJ (DT:[832..835] The)
      (ADJP (RBS:[836..840] most) (JJ:[841..847] common))
      (NN:[848..856] mutation) (NN:[857..861] site))
    (VP (VBD:[862..865] was)
      (NP-PRD
        (NP (NN:[866..872] Ha-ras)
           (NN:[873..878] codon) (CD:[879..881] 61))
        (PP (IN:[882..886] with)
          (NP
            (NML (NN:[887..890] Gln) (SYM:[890..894] ----) (NN:[894..897] Arg))
            (NN:[899..911] substitution)))))
    (.:[911..912] .)))

;sentence 8 Span:913..1062
;Two ras mutations at codon 61 (Gln----Lys in N-ras and Gln----Arg  in Ha-ras)
;were found in a microfollicular adenoma specimen from Eastern  Hungary.
;[917..920]:gene-rna:"ras"
;[921..930]:variation-event:"mutations"
;[934..942]:variation-location:"codon 61"
;[944..947]:variation-state-original:"Gln"
;[951..954]:variation-state-altered:"Lys"
;[958..963]:gene-rna:"N-ras"
;[968..971]:variation-state-original:"Gln"
;[975..978]:variation-state-altered:"Arg"
;[983..989]:gene-rna:"Ha-ras"
;[1007..1030]:malignancy:"microfollicular adenoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[913..916] Two) (NN:[917..920] ras) (NNS:[921..930] mutations))
      (PP-LOC (IN:[931..933] at)
        (NP (NN:[934..939] codon) (CD:[940..942] 61)))
      (PRN (-LRB-:[943..944] -LRB-)
        (NP
          (NP (NN:[944..947] Gln) (SYM:[947..951] ----) (NN:[951..954] Lys))
          (PP-LOC (IN:[955..957] in)
            (NP (NN:[958..963] N-ras))))
        (CC:[964..967] and)
        (NP
          (NP (NN:[968..971] Gln) (SYM:[971..975] ----) (NN:[975..978] Arg))
          (PP-LOC (IN:[980..982] in)
            (NP (NN:[983..989] Ha-ras))))
        (-RRB-:[989..990] -RRB-)))
    (VP (VBD:[991..995] were)
      (VP (VBN:[996..1001] found)
        (NP-1 (-NONE-:[1001..1001] *))
        (PP-LOC (IN:[1002..1004] in)
          (NP
            (NP (DT:[1005..1006] a)
               (JJ:[1007..1022] microfollicular) (NN:[1023..1030] adenoma)
              (NN:[1031..1039] specimen))
            (PP-LOC (IN:[1040..1044] from)
              (NP (JJ:[1045..1052] Eastern) (NNP:[1054..1061] Hungary)))))))
    (.:[1061..1062] .)))

;sentence 9 Span:1063..1286
;We conclude that dietary iodine may modulate ras oncogene mutations,  and
;that in the iodide-deficient area, ras oncogene activation may play a more 
;important role in the initiation and/or maintenance of follicular tumors.
;[1108..1111]:gene-rna:"ras"
;[1172..1175]:gene-rna:"ras"
;[1268..1285]:malignancy:"follicular tumors"
(SENT
  (S
    (NP-SBJ (PRP:[1063..1065] We))
    (VP (VBP:[1066..1074] conclude)
      (SBAR
        (SBAR (IN:[1075..1079] that)
          (S
            (NP-SBJ (JJ:[1080..1087] dietary) (NN:[1088..1094] iodine))
            (VP (MD:[1095..1098] may)
              (VP (VB:[1099..1107] modulate)
                (NP
                  (NML (NN:[1108..1111] ras) (NN:[1112..1120] oncogene))
                  (NNS:[1121..1130] mutations))))))
        (,:[1130..1131] ,) (CC:[1133..1136] and)
        (SBAR (IN:[1137..1141] that)
          (S
            (PP (IN:[1142..1144] in)
              (NP (DT:[1145..1148] the)
                (ADJP (NN:[1149..1155] iodide) (HYPH:[1155..1156] -)
                      (JJ:[1156..1165] deficient))
                (NN:[1166..1170] area)))
            (,:[1170..1171] ,)
            (NP-SBJ (NN:[1172..1175] ras) (NN:[1176..1184] oncogene)
                    (NN:[1185..1195] activation))
            (VP (MD:[1196..1199] may)
              (VP (VB:[1200..1204] play)
                (NP (DT:[1205..1206] a)
                  (ADJP (RBR:[1207..1211] more) (JJ:[1213..1222] important))
                  (NN:[1223..1227] role))
                (PP (IN:[1228..1230] in)
                  (NP
                    (NP (DT:[1231..1234] the) (NN:[1235..1245] initiation)
                        (CC:[1246..1252] and/or) (NN:[1253..1264] maintenance))
                    (PP (IN:[1265..1267] of)
                      (NP (JJ:[1268..1278] follicular) (NNS:[1279..1285] tumors)))))))))))
    (.:[1285..1286] .)))

;sentence 10 Span:1288..1358
;Additional factors are, however, necessary to initiate carcinogenesis.
(SENT
  (S
    (NP-SBJ (JJ:[1288..1298] Additional) (NNS:[1299..1306] factors))
    (VP (VBP:[1307..1310] are) (,:[1310..1311] ,)
      (ADVP (RB:[1312..1319] however))
      (,:[1319..1320] ,)
      (ADJP-PRD (JJ:[1321..1330] necessary)
        (S-ADV
          (NP-SBJ (-NONE-:[1330..1330] *))
          (VP (TO:[1331..1333] to)
            (VP (VB:[1334..1342] initiate)
              (NP (NN:[1343..1357] carcinogenesis)))))))
    (.:[1357..1358] .)))

;section 11 Span:1362..1406
;PMID: 2021946 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1362..1366] PMID) (::[1366..1367] :) (CD:[1368..1375] 2021946)
        (NN:[1376..1377] -LSB-) (NNP:[1377..1383] PubMed) (::[1384..1385] -)
        (NN:[1386..1393] indexed) (IN:[1394..1397] for)
        (NNP:[1398..1406] MEDLINE-RSB-)))
